These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

780 related items for PubMed ID: 19307538

  • 1. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.
    Neurology; 2009 Mar 24; 72(12):1056-61. PubMed ID: 19307538
    [Abstract] [Full Text] [Related]

  • 2. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM.
    Neurology; 2009 Oct 27; 73(17):1353-8. PubMed ID: 19858456
    [Abstract] [Full Text] [Related]

  • 3. CSF biomarkers predict a more malignant outcome in Alzheimer disease.
    Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O.
    Neurology; 2010 May 11; 74(19):1531-7. PubMed ID: 20458070
    [Abstract] [Full Text] [Related]

  • 4. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.
    Mol Psychiatry; 2004 Jul 11; 9(7):705-10. PubMed ID: 14699432
    [Abstract] [Full Text] [Related]

  • 5. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
    Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E.
    Arch Neurol; 2010 Feb 11; 67(2):217-23. PubMed ID: 20142530
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP.
    Brain; 2007 Sep 11; 130(Pt 9):2320-6. PubMed ID: 17586559
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
    Biol Psychiatry; 2004 Nov 01; 56(9):670-6. PubMed ID: 15522251
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.
    Arch Neurol; 2009 Mar 01; 66(3):382-9. PubMed ID: 19273758
    [Abstract] [Full Text] [Related]

  • 13. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.
    Arch Neurol; 2007 Mar 01; 64(3):343-9. PubMed ID: 17210801
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.
    Herukka SK, Hallikainen M, Soininen H, Pirttilä T.
    Neurology; 2005 Apr 12; 64(7):1294-7. PubMed ID: 15824371
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. White matter lesion severity is associated with reduced cognitive performances in patients with normal CSF Abeta42 levels.
    Stenset V, Hofoss D, Johnsen L, Skinningsrud A, Berstad AE, Negaard A, Reinvang I, Gjerstad L, Fladby T.
    Acta Neurol Scand; 2008 Dec 12; 118(6):373-8. PubMed ID: 18510598
    [Abstract] [Full Text] [Related]

  • 20. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia.
    Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE, Lindau M, Eriksdotter-Jönhagen M.
    Neurobiol Aging; 2008 Oct 12; 29(10):1466-73. PubMed ID: 17512092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.